Uncategorized
Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative therapies for ocular diseases, today announced positive top line results for the ADAGIO study, a Phase 1/2a study of intravitreal GB-102 (sunitinib malate) in patients with wet age-related macular degeneration (AMD), the leading cause of blindness in the developed world for people age 50 and older. These data were presented by David S. Boyer, M.D., of Retina